Full-Time

Technical Consultant

Confirmed live in the last 24 hours

Veeva Systems

Veeva Systems

5,001-10,000 employees

Quality and regulatory software solutions provider

Compensation Overview

$75k - $150kAnnually

+ Variable Bonus + Stock Bonus

Mid, Senior

Company Historically Provides H1B Sponsorship

Remote in USA

Category
Backend Engineering
Software Engineering
Required Skills
Java
REST APIs
Requirements
  • 4+ years of programming in Java programming language and basic knowledge of front-end technologies.
  • Strong understanding of implementation methodologies for SaaS and IaaS solutions.
  • Proficiency in Java SDK, Web Services and API based integrations
  • Proven ability to thrive in fast-paced, high-growth environments
  • Willingness and ability to travel as required by project demands.
Responsibilities
  • Develop and extend application capabilities through Java-based solutions using the Vault Java SDK
  • Design and implement cloud-based integrations using REST APIs
  • Manage and support integration and development projects and resources
  • Provide subject matter expertise on the Veeva Vault product functionality and APIs
  • Work closely with customers to establish solutions at the business and technical level
  • Take complex customer and vendor concepts and articulate them to audiences of varying perception levels.
Desired Qualifications
  • Experience in the life sciences industry, focusing on commercial or R&D functions
  • Experience developing custom solutions on the Salesforce platform
  • Familiarity with cloud platforms such as AWS, Azure, or GCP
  • Experience working in a consulting role working with matrix teams.
  • Experience in configuring SSO solutions for seamless access and integration across applications.

Veeva Systems offers software solutions for quality, regulatory, and advertising claims management, focusing on consumer products and chemical companies. Their cloud-based platform provides visibility and traceability throughout the product journey, helping clients ensure compliance with regulations while bringing products to market efficiently. Veeva stands out from competitors by addressing the specific challenges of the chemical and consumer goods industries, building on its experience in the life sciences sector. The company's goal is to support clients in delivering high-quality, safe, and sustainable products.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Pleasanton, California

Founded

2007

Simplify Jobs

Simplify's Take

What believers are saying

  • Veeva's partnership with Boehringer Ingelheim enhances clinical trial efficiency and collaboration.
  • Veeva's revenue grew 16% in fiscal year 2025, showcasing strong financial performance.
  • The rise of digital health platforms offers integration opportunities for Veeva's solutions.

What critics are saying

  • Emerging cloud-based software providers could erode Veeva's market share.
  • Rapid technological advancements may strain Veeva's resources and impact profitability.
  • Data privacy concerns and regulatory scrutiny could affect Veeva's operations.

What makes Veeva Systems unique

  • Veeva Systems specializes in cloud-based software for the life sciences industry.
  • Veeva's subscription model ensures continuous updates and a steady revenue stream.
  • Veeva Development Cloud integrates clinical, regulatory, and quality data for streamlined processes.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Parental leave

PTO

Free food

Health, dental, & vision insurance

Gym membership reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

2%

2 year growth

0%
PR Newswire
Mar 11th, 2025
Boehringer Ingelheim Partners With Veeva To Launch 'One Medicine Platform'

Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseasesINGELHEIM, Germany and BARCELONA, Spain, March 11, 2025 /PRNewswire/ -- Today, Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer's One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They first announced the One Medicine collaboration in March 2022. The unified platform brings together data and processes across clinical, regulatory, and quality, enabling Boehringer to streamline its product development. With the One Medicine Platform, Boehringer can seamlessly connect data across functions, optimize trial efficiency and collaboration with research sites, and accelerate the delivery of new medicines to treat currently incurable diseases."Together with Veeva, Boehringer has advanced its approach to clinical trials and is fulfilling our pledge to accelerate the delivery of innovative, life-transforming treatments to patients across the world," said Oliver Fink, head of learning, process and digitalization at Boehringer Ingelheim. "Veeva Development Cloud provides the technology foundation for Boehringer's One Medicine Platform, giving our teams the flexibility to design and run studies with greater speed, efficiency, and compliance.""By connecting clinical, regulatory, and quality on Veeva Development Cloud, Boehringer unifies data and breaks down silos across teams to accelerate drug development and approvals," said Rik van Mol, senior vice president, Veeva Development Cloud. "This is an exciting milestone toward realizing Veeva and Boehringer's shared mission to advance the use of data and technology to modernize clinical trials and deliver better patient outcomes."Veeva Development Cloud is the technology foundation for product development, bringing together clinical, quality, regulatory, and safety applications to simplify end-to-end business processes and deliver process excellence.Additional InformationFor more on Veeva Development Cloud, visit: veeva.com/DevelopmentCloudAbout Boehringer IngelheimBoehringer Ingelheim is a biopharmaceutical company active in both human and animal health

PharmiWeb
Mar 11th, 2025
Boehringer Ingelheim Partners With Veeva To Launch ‘One Medicine Platform’

Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseasesLondon, UK — 11 March 2025 — ​​​Today, ​Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud​.​​ They ​first announced the One Medicine collaboration in March 2022.​ ​The unified platform brings together data and processes across clinical, regulatory, and quality, enabling Boehringer to streamline its product development.With the One Medicine Platform, Boehringer can seamlessly connect data across functions, optimise trial efficiency and collaboration with research sites, and accelerate the delivery of new medicines to treat currently incurable diseases.The unified platform brings together data and processes across clinical, regulatory, and quality, enabling Boehringer to streamline its product development. With the One Medicine Platform, Boehringer can seamlessly connect data across functions, optimize trial efficiency and collaboration with research sites, and accelerate the delivery of new medicines to treat currently incurable diseases.“Together with Veeva, Boehringer has advanced its approach to clinical trials and is fulfilling our pledge to accelerate the delivery of innovative, life-transforming treatments to patients across the world,” said Oliver Fink, head of learning, process and digitalisation at Boehringer Ingelheim. “Veeva Development Cloud provides the technology foundation for Boehringer’s One Medicine Platform, giving our teams the flexibility to design and run studies with greater speed, efficiency, and compliance.”“By connecting clinical, regulatory, and quality on Veeva Development Cloud, Boehringer unifies data and breaks down silos across teams to accelerate drug development and approvals,” said Rik van Mol, senior vice president, Veeva Development Cloud. “This is an exciting milestone toward realising Veeva and Boehringer’s shared mission to advance the use of data and technology to modernise clinical trials and deliver better patient outcomes.”Veeva Development Cloud is the technology foundation for product development​,​ bringing together clinical, quality, regulatory, and safety applications to simplify end-to-end business processes and deliver process excellence.Additional InformationFor more on Veeva Development Cloud, visit: veeva.com/DevelopmentCloudAbout Boehringer IngelheimBoehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain

Investing.com
Mar 6th, 2025
Citi maintains Veeva stock Buy rating, $307 target post Q4 beat

Additionally, Veeva Systems secured its fourth top 20 customer in the Safety category and witnessed a top 20 customer commit comprehensively to its clinical solutions.

PR Newswire
Mar 5th, 2025
Veeva Announces Fourth Quarter And Fiscal Year 2025 Results

Fiscal Year 2025 Total Revenues of $2,746.6M, up 16% Year Over YearQ4 Total Revenues of $720.9M, up 14% Year Over Year. Fiscal Year 2025 Subscription Services Revenues of $2,284.7M, up 20% Year Over YearQ4 Subscription Services Revenues of $608.6M, up 17% Year Over Year. PLEASANTON, Calif., March 5, 2025 /PRNewswire/ -- Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its fourth quarter and fiscal year ended January 31, 2025

Simply Wall St
Mar 5th, 2025
Veeva Systems (NYSE:VEEV) Launches Innovative CRM Pulse For Global Healthcare Engagement Metrics

Veeva Systems (NYSE:VEEV) launches innovative CRM Pulse for global healthcare engagement metrics.